Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 16608
Corporate User License Price USD 750
Corporate User License Price INR 49823
Site License Price USD 500
Site License Price INR 33215
Request a Quote

Report Title

TaiMed Biologics Inc (4147)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

TaiMed Biologics Inc (4147)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

TaiMed Biologics Inc (4147)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

TaiMed Biologics Inc (4147)-Pharmaceuticals & Healthcare-Deals and Alliances Profile



Executive Summary

Summary

TaiMed Biologics Inc (TMB) is a biotechnology company that discovers, develops and delivers novel medicines for the prevention and treatment of viral infectious diseases. The company's products pipeline includes TMB-355, TMB-607, TMB-571 and others. Its TMB-355 is a proprietary humanized anti-CD4 monoclonal antibody, developed for the treatment of HIV/AIDS. TMB's TMB-607 is a novel HIV-1 protease inhibitor that is developed using a nanotechnology formulation for subcutaneous and intramuscular injections. The company's TMB-571 is a small molecule inhibitor against wild-type neuraminidases, both H1N1 and H5N1 viruses. It also develops a second generation TMB-355 for improving TMB-355 (ibalizumab) and to neutralize HIV in blood to improve anti-viral potency. It has presence in Taiwan and the US. TMB is headquartered in Taipei, Taiwan.

TaiMed Biologics Inc (4147)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

TaiMed Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 11

Licensing Agreements 12

TaiMed Biologics Enters into Licensing Agreement with ADARC 12

TaiMed Biologics Enters Into Licensing Agreement With Ambrilia Biopharma 12

Equity Offering 13

TaiMed Biologics Plans to Raise USD0.2 Million in Private Placement of Shares 13

TaiMed Biologics Raises USD104.8 Million in Public Offering of Shares 14

Asset Transactions 15

Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 15

TaiMed Biologics Inc-Key Competitors 17

Key Employees 18

Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

Government and Public Interest 20

Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 20

Product News 22

11/01/2016: Theratechnologies Announces Update from its Healthcare Analyst Day Meeting 22

02/15/2017: Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab 23

Clinical Trials 24

Feb 14, 2017: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab 24

Jan 17, 2017: Theratechnologies Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017 26

Nov 10, 2016: Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab 27

Nov 02, 2016: Market Studies on Ibalizumab for the United States Market 28

Oct 28, 2016: Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016 29

Oct 24, 2016: Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial 31

Aug 18, 2016: Ibalizumab Phase III Study Primary End-Point Results to Be Presented at IDWeek 2016 32

May 24, 2016: Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial 33

Apr 27, 2016: Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

TaiMed Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

TaiMed Biologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

TaiMed Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Theratechnologies Enters into Co-Marketing Agreement with TaiMed Biologics 11

TaiMed Biologics Enters into Licensing Agreement with ADARC 12

TaiMed Biologics Enters Into Licensing Agreement With Ambrilia Biopharma 12

TaiMed Biologics Plans to Raise USD0.2 Million in Private Placement of Shares 13

TaiMed Biologics Raises USD104.8 Million in Public Offering of Shares 14

Theratechnologies Acquires Commercial Rights to Ibalizumab from TaiMed Biologics 15

TaiMed Biologics Inc, Key Competitors 17

TaiMed Biologics Inc, Key Employees 18

TaiMed Biologics Inc, Subsidiaries 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

TaiMed Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand